GregoryAMastersMD

Oncology • Newark, DE

Gastrointestinal Cancer, Neuro-Oncology, Thoracic Cancer

Associate Professor at Thomas Jefferson Medical School PI of NCORP at Christiana Care Health System

Join to view full profile

Dr. Masters is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Masters' full profile

Already have an account?

Office
4701 Ogletown Stanton Rd
Suite 2200
Newark, DE 19713
Phone+1 302-366-1200

Fax+1 302-366-1700
Is this information wrong?

Education & Training

University of ChicagoFellowship, Hematology and Medical Oncology, 1993 - 1996
University of Pennsylvania Health SystemResidency, Internal Medicine, 1990 - 1993
Northwestern University The Feinberg School of MedicineClass of 1990

Certifications & Licensure

DE State Medical License 2003 - 2025
IL State Medical License 1993 - 2005
PA State Medical License 1992 - 1994
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Philadelphia Magazine Castle Connolly, 2014
America's Top Doctors Castle Connolly, 2002-2014
America's Top Doctors for Cancer Castle Connolly, 2005-2013
Fellow (FASCO) American Society of Clinical Oncologists, 2010
Fellow (FACP) American College of Physicians, 2005
Join now to see all

Clinical Trials

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer Start of enrollment: 1999 Aug 01
Terminated
Phase 1, Phase 2
Carboplatin Plus Vinorelbine in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer Start of enrollment: 1999 Aug 01
Completed
Phase 1, Phase 2
Combination Chemotherapy in Treating Patients With Advanced Non-Small Cell Lung Cancer Start of enrollment: 2002 Oct 04
Completed
Phase 2
Pentostatin, Cyclophosphamide, and Rituximab Followed By Campath-1H in Patients With Relapsed or Refractory B-Cell CLL Start of enrollment: 2005 Apr 14
Completed
Phase 2
Combination Chemotherapy and Alemtuzumab in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia Start of enrollment: 2006 Jun 01
Terminated
Phase 2
Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Start of enrollment: 2006 Aug 01
Completed
Phase 2
Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery Start of enrollment: 2007 Jun 01
Active, not recruiting
Phase 3
High-Dose or Standard-Dose Radiation Therapy and Chemotherapy With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery Start of enrollment: 2007 Nov 01
Completed
Phase 3
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Start of enrollment: 2008 Aug 08
Active, not recruiting
Phase 3
Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide Start of enrollment: 2008 Mar 01
Active, not recruiting
Phase 3
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia Start of enrollment: 2009 Jan 29
Active, not recruiting
Phase 3
Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery Start of enrollment: 2009 Oct 28
Completed
Phase 3
Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis Start of enrollment: 2010 Nov 01
Completed
Phase 3
Induction Chemotherapy Followed By Cetuximab and Radiation in HPV-Associated Resectable Stage III/IV Oropharynx Cancer Start of enrollment: 2010 Aug 11
Completed
Phase 2
Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer Start of enrollment: 2011 Jan 07
Completed
Phase 2
Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer Start of enrollment: 2010 Sep 21
Active, not recruiting
Phase 2
Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery Start of enrollment: 2010 Sep 17
Completed
Phase 2
Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma Start of enrollment: 2011 Jan 24
Active, not recruiting
Phase 3
Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer Start of enrollment: 2011 May 16
Completed
Not Applicable
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery Start of enrollment: 2011 May 25
Active, not recruiting
Phase 3
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery Start of enrollment: 2012 Aug 08
Active, not recruiting
Phase 3
Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery Start of enrollment: 2013 Jan 18
Active, not recruiting
Phase 2
Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma Start of enrollment: 2013 Aug 27
Active, not recruiting
Phase 2
Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery Start of enrollment: 2014 Jan 24
Active, not recruiting
Phase 2
Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer Start of enrollment: 2015 Aug 27
Completed
Phase 2
Collection and Storage of Tissue and Blood Samples From Patients With Cancer Start of enrollment: 2015 May 19
Recruiting
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer Start of enrollment: 2015 Jul 26
Recruiting
Phase 3
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2023.3.
Owen, D. H., Ishmael A Jaiyesimi, Natasha B Leighl, Nofisat Ismaila, Krishna Alluri, Narjust Florez, Shirish Gadgeel, Gregory Masters, Erin L Schenk, Bryan J Schneider...> ;Journal of Clinical Oncology. 2024 Apr 10
Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2023.3.
Owen, D. H., Ishmael A Jaiyesimi, Natasha B Leighl, Nofisat Ismaila, Krishna Alluri, Narjust Florez, Shirish Gadgeel, Gregory Masters, Erin L Schenk, Bryan J Schneider...> ;Journal of Clinical Oncology. 2024 Apr 10
The Inherited KRAS-variant as a Biomarker of Cetuximab Response in NSCLC.
Joanne B Weidhaas, Chen Hu, Ritsuko Komaki, Gregory A Masters, George R Blumenschein, Joe Y Chang, Bo Lu, Adam P Dicker, Jeffrey A Bogart, Yolanda I Garces, Samir Nara...> ;Cancer Research Communications. 2023 Oct 11
2 citations
Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2023.2.
Dwight H Owen, Navneet Singh, Nofisat Ismaila, Gregory Masters, Gregory J Riely, Andrew G Robinson, Bryan J Schneider, Ishmael A Jaiyesimi> ;Journal of Clinical Oncology. 2023 Aug 20
Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit.
Benjamin J Bulen, Nickolay A Khazanov, Daniel H Hovelson, Laura E Lamb, Marc Matrana, Mark E Burkard, Eddy Shih-Hsin Yang, William J Edenfield, Elizabeth Claire Dees, ...> ;Cancer Research Communications. 2023 Jul 1
6 citations
Development and validation of an integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit.
Tomlins, S., Khazanov, N., Bulen, B., Hovelson, D., Shreve, M., Lamb, L., Matrana, M., Burkard, M., Yang, E., Edenfield, W., Dees, E., Onitilo, A., Thompson, M., Buchs...> ;Communications Medicine. 2023 Feb 7
Consensus statement and clinical pathway for the management of colon cancer with peritoneal metastases in the state of Delaware.
Jesus Esquivel, Nicholas Petrelli, James Spellman, Joseph Bennett, Suguna Chirla, Jamil Khatri, Gregory Masters> ;Surgical Oncology. 2023 Dec 1
12 citations
High-Dose Once-Daily Thoracic Radiotherapy in Limited-Stage Small-Cell Lung Cancer: CALGB 30610 (Alliance)/RTOG 0538.
Jeffrey Bogart, Xiaofei Wang, Gregory Masters, Junheng Gao, Ritsuko Komaki, Laurie E Gaspar, John Heymach, James Bonner, Charles Kuzma, Saiama Waqar, William Petty, Th...> ;Journal of Clinical Oncology. 2023 May 1
26 citations
Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2022.2.
Dwight H Owen, Navneet Singh, Nofisat Ismaila, Elizabeth Blanchard, Paul Celano, Narjust Florez, Dharamvir Jain, Natasha B Leighl, Hirva Mamdani, Gregory Masters, Pame...> ;Journal of Clinical Oncology. 2023 Feb 10
10 citations
Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2022.2.
Dwight H Owen, Navneet Singh, Nofisat Ismaila, Elizabeth Blanchard, Paul Celano, Narjust Florez, Dharamvir Jain, Natasha B Leighl, Hirva Mamdani, Gregory Masters, Pame...> ;Journal of Clinical Oncology. 2023 Feb 10
39 citations
Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline.
Navneet Singh, Sarah Temin, Sherman Baker Jr, Elizabeth Blanchard, Julie R Brahmer, Paul Celano, Narjust Duma, Peter M Ellis, Ivy B Elkins, Rami Y Haddad, Paul J Heske...> ;Journal of Clinical Oncology. 2022 Oct 1
39 citations
Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline.
Navneet Singh, Sarah Temin, Sherman Baker Jr, Elizabeth Blanchard, Julie R Brahmer, Paul Celano, Narjust Duma, Peter M Ellis, Ivy B Elkins, Rami Y Haddad, Paul J Heske...> ;Journal of Clinical Oncology. 2022 Oct 1
10 citations
Alliance A082002 -a randomized phase II/III trial of modern immunotherapy-based systemic therapy with or without SBRT for PD-L1-negative, advanced non-small cell lung ...
Steven E Schild, Xiaofei Wang, Christine M Bestvina, Terence Williams, Greg Masters, Anurag K Singh, Thomas E Stinchcombe, Joseph K Salama, Steven Wolf, Tyler Zemla, N...> ;Clinical Lung Cancer. 2022 Jul 1
1 citations
A Review of Concurrent Chemo/Radiation, Immunotherapy, Radiation Planning, and Biomarkers for Locally Advanced Non-small Cell Lung Cancer and Their Role in the Develop...
John Michael Varlotto, Zhuoxin Sun, Bonnie Ky, Jenica Upshaw, Thomas J Fitzgerald, Max Diehn, Christine Lovly, Chandra Belani, Kurt Oettel, Gregory Masters, Matthew Ha...> ;Clinical Lung Cancer. 2022 Nov 1
7 citations
Attention to diet, exercise, and weight in oncology care: Results of an American Society of Clinical Oncology national patient survey.
Jennifer A Ligibel, Lori J Pierce, Catherine M Bender, Tracy E Crane, Christina Dieli-Conwright, Judith O Hopkins, Gregory A Masters, Caroline Schenkel, Elizabeth Garr...> ;Cancer. 2022 Jul 15
Mature Outcomes of 61.2 Gy Concomitant Boost (CB) Thoracic Radiotherapy (TRT) in Limited Stage Small Cell Lung Cancer (LSCLC): CALGB 30610 (Alliance) / RTOG 0538.
Jeffrey A. Bogart, Xiaofei Wang, Gregory A. Masters, Junheng Gao, R.U. Komaki-Cox, Laurie E. Gaspar, John V. Heymach, Michael C. Dobelbower, C. Kuzma, Saiama N. Waqar,...> ;International Journal of Radiation Oncology Biology Physics. 2021 Nov 1
271 citations
Society for immunotherapy of cancer (sitc) clinical practice guideline on immune checkpoint inhibitor-related adverse events
Julie R. Brahmer, Hamzah Abu-Sbeih, Paolo A. Ascierto, Jill Brufsky, Laura C. Cappelli, Frank B. Cortazar, David E. Gerber, Lamya Hamad, Eric Hansen, Douglas B. Johnso...> ;Journal for Immunotherapy of Cancer. 2021 Jun 1
8 citations
Short Communication: Interim toxicity analysis for patients with limited stage small cell lung cancer (LSCLC) treated on CALGB 30610 (Alliance) / RTOG 0538.
Jeffrey A. Bogart, Xiaofei Wang, Gregory A. Masters, Junheng Gao, R.U. Komaki, Laurie E. Gaspar, J. Heymach, Michael C. Dobelbower, Charles Kuzma, Thomas E. Stinchcomb...> ;Lung Cancer. 2021 Apr 18
105 citations
Analysis of classical neutrophils and polymorphonuclear myeloid-derived suppressor cells in cancer patients and tumor-bearing mice
Filippo Veglia, Ayumi Hashimoto, Harsh Dweep, Emilio Sanseviero, Alessandra De Leo, Evgenii N. Tcyganov, Andrew V. Kossenkov, Charles Mulligan, Brian Nam, Gregory A. M...> ;The Journal of Experimental Medicine. 2021 Apr 5
134 citations
Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update.
Nasser H Hanna, Andrew G Robinson, Sarah Temin, Sherman Baker Jr, Julie R Brahmer, Peter M Ellis, Laurie E Gaspar, Rami Y Haddad, Paul J Hesketh, Dharamvir Jain, Ishma...> ;Journal of Clinical Oncology. 2021 Mar 20
46 citations
Immune suppressive activity of myeloid-derived suppressor cells in cancer requires inactivation of the type I interferon pathway
Kevin Alicea-Torres, Emilio Sanseviero, Jun Gui, Jinyun Chen, Filippo Veglia, Qiujin Yu, Laxminarasimha Donthireddy, Andrew V. Kossenkov, Cindy Lin, Shuyu Fu, Charles ...> ;Nature Communications. 2021 Mar 19
4 citations
A Review of Immunotherapy for Stage III and Metastatic Non-Small Cell Lung Cancer and the Rationale for the ECOG-ACRIN EA5181 Study.
John M. Varlotto, Z. Sun, Bonnie Ky, Jenica N. Upshaw, Sharyn I. Katz, Thomas J. Fitzgerald, Heather A. Wakelee, Maximilian Diehn, David A. Mankoff, Christine Lovely, ...> ;The Oncologist. 2021 Jun 1
84 citations
Distinct Populations of Immune-Suppressive Macrophages Differentiate from Monocytic Myeloid-Derived Suppressor Cells in Cancer.
Tae Kyoung Kwak, Fang Wang, Hui Deng, Thomas Condamine, Vinit Kumar, Michela Perego, Andrew V. Kossenkov, Luis J. Montaner, Xiaowei Xu, Wei Xu, Cathy Zheng, Lynn M. Sc...> ;Cell Reports. 2020 Dec 29
276 citations
Clinical Cancer Advances 2020: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.
Merry Jennifer Markham, Kerri Wachter, Neeraj Agarwal, Monica M Bertagnolli, Susan Marina Chang, William Dale, Catherine S M Diefenbach, Carlos Rodriguez-Galindo, Dani...> ;Journal of Clinical Oncology. 2020 Apr 1
233 citations
Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non-Small-Cell Lung Cancer.
Jeffrey D. Bradley, Chen Hu, Ritsuko Komaki, Gregory A. Masters, George R. Blumenschein, Steven E. Schild, Jeffrey A. Bogart, Kenneth M. Forster, Anthony M. Magliocco,...> ;Journal of Clinical Oncology. 2020 Mar 1
Join now to see all

Journal Articles

Unique Pattern of Neutrophil Migration and Function During Tumor Progression
Neil Hockstein, Charles Mulligan, Robert H Vonderheide, Gregory Masters, Nature